

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the above-identified application.

Claims:

1. - 73. (Cancelled)

74. (Cancelled) A therapeutic composition comprising an amyloid-beta (A β) polypeptide linked to a therapeutic non-A β polypeptide, and a sterile pharmaceutically acceptable carrier or excipient,
wherein said therapeutic non-A β polypeptide improves or stabilizes one or more clinical features of a CNS disorder in a patient,
wherein the clinical features of a CNS disorder are selected from the group consisting of cognitive function, memory, behavior, language skills, motor skills and patient rigidity,
wherein the non-A β polypeptide is an antibody,
and wherein the antibody is polyamine modified.

75. (Currently Amended) The composition of claim ~~[[74]]~~76, wherein the antibody is a monoclonal polyamine modified antibody.

76. (Currently Amended) A therapeutic composition comprising an amyloid-beta (A β) polypeptide linked to an anti- A β antibody, and a sterile pharmaceutically acceptable carrier or excipient,
~~The composition of claim 75 wherein the antibody is monoclonal polyamine modified and antibody has specific binding affinity for amyloid peptide comprising residues 1-39 of SEQ ID NO:1 [.]~~
wherein the anti- A β antibody improves or stabilizes one or more clinical features of a CNS disorder in a patient,
wherein the clinical features of a CNS disorder are selected from the group consisting of cognitive function, memory, behavior, language skills, motor skills and patient rigidity.

77. (Currently Amended) The composition of claim ~~[[74]]~~76, wherein the ~~non-amyloid-beta (A β) polypeptide~~ polyamine modified anti-A β antibody is a humanized antibody.

78. (New) The composition of claim 76, wherein the polyamine modified anti-A β antibody comprises a Fab fragment.

79. (New) The composition of claim 76, wherein the polyamine modified anti-A β antibody comprises a single chain Fv antibody fragment.

80. (New) The composition of claim 76, wherein the polyamine modified anti-A β antibody is labeled with a radioisotope or a contrast agent.

81. (New) The composition of claim 76, wherein the polyamine modified anti-A β antibody is labeled with a contrast agent.